Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Pieris Pharmaceuticals
Pieris Pharmaceuticals
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Scleroderma treatment by Certa Therapeutics granted US FDA fast track
FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
Naobios and Sumagen sign exclusive partnership to develop HIV vaccine
Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
Rapid increase in purchasing teams expected at CPHI North America
Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Bio-Rad and Oncocyte partner to commercialise transplant monitoring with Droplet Digital PCR
The collaboration aims to provide researchers with tools to enable transformational monitoring of key biomarkers in solid tissue transplants
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Media
Merck is set to lead pharmaceutical licensing deals in 2018
GlobalData, a specialist data and analytics company, expects that 2018 is likely to be Merck’s year in terms of research and development collaboration
Media
Pieris Pharmaceuticals appoints new Chairman for Board of Directors
Pharmaceutical
Pieris Pharmaceuticals appoints James Geraghty to its Board of Directors
Regulatory
Commercialised anticalin inhaled treatments
Pieris Pharmaceuticals and AstraZeneca collaborate to develop and commercialise treatments for respiratory diseases
Ingredients
Pieris announces first cancer immunotherapy collaboration
Agreement with Roche leverages proprietary Anticalin technology platform
Pharmaceutical
Pieris Pharmaceuticals appoints Chief Development Officer
Louis Matis takes up the position at the biotechnology company
Research & Development
Pieris Pharmaceuticals and the University of Melbourne receive grant
To advance Anticalin-based therapeutic for inhaled delivery to treat asthmatics
Subscribe now